John Wijdenes

Best Publications

• Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.

  T. C. T. M. Van Der Pouw Kraan;L. C. M. Boeije;R. J. T. Smeenk;J. Wijdenes

  1000
  Citations

• Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.

  Luis Llorente;Weiping Zou;Yves Levy;Yvonne Richaud-Patin

  686
  Citations

• Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

  Luis Llorente;Yvonne Richaud-Patin;Carlos García-Padilla;Emmanuel Claret

  590
  Citations

• Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

  Joseph T. Beck;Su-Ming Hsu;John Wijdenes;Regis Bataille

  563
  Citations

• Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.

  B Klein;J Wijdenes;XG Zhang;M Jourdan

  527
  Citations

• In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity.

  Luis Llorente;Yvonne Richaud‐Patin;Renato Fior;Jorge Alcocer‐Varela

  472
  Citations

• Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice.

  Eric Tartour;François Fossiez;Isabelle Joyeux;Annie Galinha

  444
  Citations

• A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1.

  John Wijdenes;Wim C. Vooijs;Claude Clément;Jacob Post

  443
  Citations

• Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function.

  Jan Kubach;Petra Lutter;Tobias Bopp;Sabine Stoll

  279
  Citations

• Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

  Unknown

  279
  Citations

• Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus.

  L Llorente;Y Richaud-Patin;J Wijdenes;J Alcocer-Varela

  276
  Citations

• Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses

  Gerhard Müller-Newen;Andrea Küster;Ulrike Hemmann;Radovan Keul

  236
  Citations

• Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms.

  D Emilie;J Wijdenes;C Gisselbrecht;B Jarrousse

  236
  Citations

• Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes.

  Unknown

  232
  Citations

• Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease.

  P Herve;M Flesch;P Tiberghien;J Wijdenes

  227
  Citations

• Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD 23 is a low affinity receptor for IgE.

  J Y Bonnefoy;J P Aubry;C Peronne;J Wijdenes

  216
  Citations

• Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10)

  P Herve;J Wijdenes;JP Bergerat;P Bordigoni

  209
  Citations

• Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis.

  Pierre Miossec;Jérǒme Briolay;Julie Dechanet;John Wijdenes

  197
  Citations

• Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.

  Pierfrancesco Tassone;Victor S. Goldmacher;Paola Neri;Antonella Gozzini

  188
  Citations

• The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells

  Michel Jourdan;Martine Ferlin;Eric Legouffe;Mira Horvathova

  187
  Citations